Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome

Table 1 Characteristics of study subjects and baseline data

Variable	Unit	Value
Age	yr	66.6 ± 12.6
Sex (men/women)	%	196/53 (79.0/21.0)
Medical history
Myocardial infarction	%	11 (4.4)
Unstable angina pectoris	%	5 (2.0)
Angina pectoris	%	30 (12.0)
Atrial fibrillation	%	14 (5.6)
Cerebral infarction	%	17 (6.8)
Diabetes mellitus	%	84 (33.7)
Hypertension	%	149 (59.8)
Smoking	%	131 (52.6)
Medication
Calcium channel blocker	%	107 (43.0)
ACE-I/ARB	%	81 (32.5)
Beta blocker	%	22 (8.8)
Loop diuretics	%	20 (8.0)
Nitrates	%	37 (14.9)
Statin	%	67 (26.9)
Fibrate	%	5 (2.0)
Ezetimibe	%	1 (0.4)
Insulin	%	12 (4.8)
SGLT2 inhibitor	%	2 (0.8)
Biguanide	%	8 (3.2)
DPP4 Inhibitor	%	18 (7.2)
BMI	kg/m2	23.8 ± 3.9
Systolic blood pressure	mmHg	134.0 ± 32.0
Heart rate	bpm	77.0 ± 22.0
Laboratory data
Hemoglobin	mg/dL	13.4 ± 2.0
Glucose	mg/dL	190.2 ± 91.3
Hemoglobin A1c	%	6.5 ± 1.3
Total cholesterol	mg/dL	189.0 ± 41.1
Triglyceride	mg/dL	118.81 ± 76.31
LDL-cholesterol	mg/dL	122.4 ± 36.6
non-HDL cholesterol	mg/dL	146.2 ± 40.0
BNP	pg/mL	278.9 ± 1288.0
Creatinine	IU/L	1.2 ± 1.6
Alanine aminotransferase	IU/L	58.5 ± 306.5
peak CK	IU/L	2973.0 ± 3257.0
peak CK-MB	IU/L	300.0 ± 668.0

Values are the number of subjects in each category with percent proportion in parentheses [n (%)] or data expressed as mean ± SD. ACEI: Angiotensin-converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; BMI: Body mass index; BNP: Brain natriuretic peptide; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CK-MB: Creatine kinase-myocardial isoform; DPP-4: Dipeptidyl peptidase-4; SGLT2: Sodium glucose cotransporter-2.